Clinical Trial Update: A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of CHF 5259 inhalation in COPD completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 5259 (CHF 5259)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD, Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-06-15